[1] R. Mehta and A. D. Shapiro, “Plasminogen deficiency,” Haemophilia, vol. 14, no. 6, pp. 1261–1268, 2008.
[2] P. Gurman, O. R. Miranda, A. Nathan, C. Washington, Y. Rosen, and N. M. Elman, “Recombinant tissue plasminogen activators (rtPA): a review,” Clin Pharmacol Ther, vol. 97, no. 3, pp. 274–285, 2015.
[3] D. Kireyev, H. C. Tan, and K. K. Poh, “Management of acute ST-elevation myocardial infarction: reperfusion options,” Ann Acad Med Singapore, vol. 39, pp. 927–933, 2010.
[4] P. Goldstein and E. Wiel, “Management of prehospital thrombolytic therapy in ST-segment elevation acute coronary syndrome (< 12 hours).,” Minerva Anestesiol., vol. 71, no. 6, pp. 297–302, 2005.
[5] G. H. Guyatt, E. A. Akl, M. Crowther, D. D. Gutterman, and H. J. Schuünemann, “Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2 Suppl, p. 7S, 2012.
[6] G. Melandri, F. Vagnarelli, D. Calabrese, F. Semprini, S. Nanni, and A. Branzi, “Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction,” Vasc. Health Risk Manag., vol. 5, p. 249, 2009.
[7] S. G. Goodman and W. J. Cantor, “Drip‑and‑ship for acute ST‑segment myocardial infarction,” Pol. Arch. Med. WEWNĘTRZNEJ, vol. 119, no. 11, pp. 726–730, 2009.
[8] J. Röther, G. A. Ford, and V. N. S. Thijs, “Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities,” Cerebrovasc. Dis., vol. 35, no. 4, pp. 313–319, 2013.
[9] A. Baratloo et al., “Tissue plasminogen activator: A literature review,” Arch Neurosci, vol. 3, no. 1, p. e30452, 2016.
[10] M. T. Mullen, J. M. Pisapia, S. Tilwa, S. R. Messé, and S. C. Stein, “Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+ intra-arterial thrombolysis,” Stroke, vol. 43, no. 9, pp. 2350–2355, 2012.
[11] B. T. Bateman et al., “Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002,” Stroke, vol. 37, no. 2, pp. 440–446, 2006.
[12] K. B. Al-Kubaisi and M. B. Al-Rikabi, “THE EFFECT OF TISSUE PLASMINOGEN ACTIVATOR ON THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION,” IRAQI J. Med. Sci., p. 278, 2000.
[13] N. A. N. Muhamad, Mm. E. MbBcHBAO, M. S. Azizan, N. A. Masani, T. S. Ling, and O. T. Siang, “Asscociation of risk factors and its bleeding complication for tenecteplase administered in acute myocardial infarction (AMI),” Med J Malaysia, vol. 68, no. 5, p. 381, 2013.
[14] H.-H. ERLEMEIER, W. Zangemeister, L. Burmester, J. Schofer, D.-G. MATHEY, and W. Bleifeld, “Bleeding after thrombolysis in acute myocardial infarction,” Eur. Heart J., vol. 10, no. 1, pp. 16–23, 1989.
[15] S. D. Berkowitz et al., “Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction,” Circulation, vol. 95, no. 11, pp. 2508–2516, 1997.
[16] P. Pheerawong and B. Plienthaisong, “Outcome of recombinant tissue plasminogen activator in ST-segment elevation myocardial infarction in Buriram Hospital,” J Med Assoc Thail Chotmaihet Thangphaet, vol. 97, no. 8, pp. 804–811, 2014.
[17] L. M. Brass, J. H. Lichtman, Y. Wang, J. H. Gurwitz, M. J. Radford, and H. M. Krumholz, “Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project,” Stroke, vol. 31, no. 8, pp. 1802–1811, 2000.
[18] J. S. Balami, B. A. Sutherland, and A. M. Buchan, “Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke,” CNS Neurol. Disord. Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord., vol. 12, no. 2, pp. 155–169, 2013.
[19] M. G. Lansberg, G. W. Albers, and C. A. C. Wijman, “Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors,” Cerebrovasc. Dis., vol. 24, no. 1, pp. 1–10, 2007.
[20] P. P. De Jaegere, A. A. Arnold, A. H. Balk, and M. L. Simoons, “Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors,” J. Am. Coll. Cardiol., vol. 19, no. 2, pp. 289–294, 1992.
[21] S. B. Soumerai, T. J. McLaughlin, D. Ross-Degnan, C. L. Christiansen, and J. H. Gurwitz, “Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old,” Arch. Intern. Med., vol. 162, no. 5, pp. 561–568, 2002.
[22] A. K. BERGER et al., “Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients,” Surv. Anesthesiol., vol. 44, no. 3, pp. 136–137, 2000.
[23] B. G. Angeja, A. C. Rundle, J. H. Gurwitz, J. M. Gore, and H. V Barron, “Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator,” Am. J. Cardiol., vol. 87, no. 5, pp. 627–630, 2001.
[24] M. Martínez-Sellés, T. Datino, and H. Bueno, “Influence of reperfusion therapy on prognosis in patients aged≥ 89 years with acute myocardial infarction,” Am. J. Cardiol., vol. 95, no. 10, pp. 1232–1234, 2005.
[25] A. Carro and J. C. Kaski, “Myocardial infarction in the elderly,” Aging Dis., vol. 2, no. 2, p. 116, 2011.